Edwards Lifesciences (EW) Announces SAPIEN 3 TAVR Receives FDA Approval For Low-Risk Patients
August 16, 2019 11:56 AM
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
